Nolan Sean P. 4

What Happened
Sean Nolan, President/CEO of Taysha Gene Therapies (TSHA), reported two sales of company stock: 136,789 shares sold on 2026-01-23 for a weighted average price of $4.75 (proceeds ≈ $649,748) and 41,312 shares sold on 2026-01-26 for a weighted average price of $4.61 (proceeds ≈ $190,448). Combined, Nolan disposed of 178,101 shares for roughly $840,196. These were sales (disposals), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-01-23: 136,789 shares; weighted avg $4.75 (individual sale prices ranged $4.635–$4.99).
  • 2026-01-26: 41,312 shares; weighted avg $4.61 (individual sale prices ranged $4.505–$4.715).
• Total sold: 178,101 shares for ≈ $840,196 in proceeds.
• Filing: Form 4 filed 2026-01-27 (Period of Report includes 2026-01-23 and 2026-01-26). Note: Form 4s are generally due within two business days of a transaction; the 2026-01-23 sale was reported four days later and may be late.
• Shares owned after the transactions: not specified in the provided filing.
• Footnotes of note:
  • F1 — Sales were made pursuant to a mandatory "sell-to-cover" to satisfy income tax withholding on vested restricted stock units (RSUs).
  • F2/F3 — Reported prices are weighted averages; Nolan offers to provide a breakdown of the number of shares sold at each individual price within the stated ranges.
  • F4 — Some securities are held by Nolan Capital, LLC; Nolan is President and has shared voting and investment power over those shares.

Context
These sales were made to cover tax liabilities related to RSU vesting (a common, routine insider action) rather than an outright directional investment decision. For retail investors, purchases by insiders often carry more interpretive weight than routine sell-to-cover transactions; this filing documents tax-related disposals rather than an indicated loss of confidence.